Recurrence Patterns and Surveillance Imaging in Pediatric Brain Tumor Survivors.
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
05 Mar 2024
05 Mar 2024
Historique:
received:
15
11
2023
accepted:
11
02
2024
medline:
6
3
2024
pubmed:
6
3
2024
entrez:
6
3
2024
Statut:
aheadofprint
Résumé
Surveillance magnetic resonance imaging (MRI) is routinely used to detect recurrence in pediatric central nervous system (CNS) tumors. The frequency of neuroimaging surveillance varies without a standardized approach. A single-institutional retrospective cohort study evaluated the frequency of recurrences. This study included 476 patients with the majority diagnosed with low-grade glioma (LGG) (n=138, 29%), high-grade glioma (HGG) (n=77, 16%), ependymoma (n=70, 15%), or medulloblastoma (n=61, 13%). LGG, HGG, and ependymoma patients more commonly had multiply recurrent disease (P=0.08), with ependymoma patients demonstrating ≥2 relapses in 47% of cases. Recurrent disease was identified by imaging more often than clinical symptoms (65% vs. 32%; P=<0.01). Patients diagnosed with meningioma demonstrated the longest mean time to first relapse (74.7 mo) whereas those with atypical teratoid rhabdoid tumor and choroid plexus carcinoma tended to have the shortest time to relapse (8.9 and 9 mo, respectively). Overall, 22 patients sustained first relapse >10 years from initial diagnosis. With a higher tendency toward detection of tumor recurrence/progression on MRI surveillance in comparison to clinical progression, surveillance imaging is necessary in routine follow up of pediatric CNS tumor survivors. With some relapses >10 years from initial diagnosis, imaging beyond this time point may be useful in particular tumor types. While the study is limited in outcome analysis, earlier detection of recurrence would lead to earlier initiation of treatment and implementation of salvage treatment regimens which can impact survival and quality of life.
Identifiants
pubmed: 38447113
doi: 10.1097/MPH.0000000000002850
pii: 00043426-990000000-00392
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Udaka YT, Yeh-Nayre LA, Amene CS, et al. Recurrent pediatric central nervous system low-grade gliomas: the role of surveillance neuroimaging in asymptomatic children. J Neurosurg Pediatr. 2013;11:119–126.
Landier W, Wallace WH, Hudson MM. Long-term follow-up of pediatric cancer survivors: education, surveillance, and screening. Pediatr Blood Cancer. 2006;46:149–158.
Main C, Stevens SP, Bailey S, et al. The impact of routine surveillance screening with magnetic resonance imaging (MRI) to detect tumour recurrence in children with central nervous system (CNS) tumours: protocol for a systematic review and meta-analysis. Syst Rev. 2016;5:143.
Stevens SP, Main C, Bailey S, et al. The utility of routine surveillance screening with magnetic resonance imaging to detect tumor recurrence/progression in children with high-grade central nervous system tumors: a systematic review. Pediatr Blood Cancer. 2019;66:e27509.
Weiser DA, Kaste SC, Siegel MJ, et al. Imaging in childhood cancer: a Society for Pediatric Radiology and Children’s Oncology Group Joint Task Force report. Pediatr Blood Cancer. 2013;60:1253–1260.
Kramer ED, Vezina LG, Packer RJ, et al. Staging and surveillance of children with central nervous system neoplasms: recommendations of the Neurology and Tumor Imaging Committees of the Children’s Cancer Group. Pediatr Neurosurg. 1994;20:254–262; discussion 262–263.
Mendel E, Levy ML, Raffel C, et al. Surveillance imaging in children with primitive neuroectodermal tumors. Neurosurgery. 1996;38:692–694; discussion 694–695.
Perreault S, Lober RM, Carret AS, et al. Surveillance imaging in children with malignant CNS tumors: low yield of spine MRI. J Neurooncol. 2014;116:617–623.
Shaw DW, Geyer JR, Berger MS, et al. Asymptomatic recurrence detection with surveillance scanning in children with medulloblastoma. J Clin Oncol. 1997;15:1811–1813.
Stevens SP, Main C, Bailey S, et al. The utility of routine surveillance screening with magnetic resonance imaging (MRI) to detect tumour recurrence in children with low-grade central nervous system (CNS) tumours: a systematic review. J Neurooncol. 2018;139:507–522.
Vassilyadi M, Shamji MF, Tataryn Z, et al. Postoperative surveillance magnetic resonance imaging for cerebellar astrocytoma. Can J Neurol Sci. 2009;36:707–712.
Kornreich L, Schwarz M, Karmazyn B, et al. Role of MRI in the management of children with diffuse pontine tumors: a study of 15 patients and review of the literature. Pediatr Radiol. 2005;35:872–879.
Korones DN, Butterfield R, Meyers SP, et al. The role of surveillance magnetic resonance imaging (MRI) scanning in detecting recurrent brain tumors in asymptomatic children. J Neurooncol. 2001;53:33–38.
Frankart AJ, Nagarajan R, Pater L. The impact of proton therapy on cardiotoxicity following radiation treatment. J Thromb Thrombolysis. 2021;51:877–883.
Mertens AC, Liu Q, Neglia JP, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2008;100:1368–1379.
Kovanlikaya A, Karabay N, Cakmakçi H, et al. Surveillance imaging and cost effectivity in pediatric brain tumors. Eur J Radiol. 2003;47:188–192.
Deimling GT, Bowman KF, Sterns S, et al. Cancer-related health worries and psychological distress among older adult, long-term cancer survivors. Psychooncology. 2006;15:306–320.
Otth M, Scheinemann K. Surveillance imaging for high-grade childhood brain tumors: What to do 10 years after completion of treatment? Pediatr Blood Cancer. 2018;65:e27311.
Sabel M, Fleischhack G, Tippelt S, et al. Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study. J Neurooncol. 2016;129:515–524.
Kim AH, Thompson EA, Governale LS, et al. Recurrence after gross-total resection of low-grade pediatric brain tumors: the frequency and timing of postoperative imaging. J Neurosurg Pediatr. 2014;14:356–364.
Dodgshun AJ, Maixner WJ, Hansford JR, et al. Low rates of recurrence and slow progression of pediatric pilocytic astrocytoma after gross-total resection: justification for reducing surveillance imaging. J Neurosurg Pediatr. 2016;17:569–572.
Dorward IG, Luo J, Perry A, et al. Postoperative imaging surveillance in pediatric pilocytic astrocytomas. J Neurosurg Pediatr. 2010;6:346–352.
Alford R, Gargan L, Bowers DC, et al. Postoperative surveillance of pediatric cerebellar pilocytic astrocytoma. J Neurooncol. 2016;130:149–154.
Torres CF, Rebsamen S, Silber JH, et al. Surveillance scanning of children with medulloblastoma. N Engl J Med. 1994;330:892–895.
Roebuck DJ, Villablanca JG, Maher K, et al. Surveillance imaging in children with medulloblastoma (posterior fossa PNET). Pediatr Radiol. 2000;30:447–450.
Klawinski D, Indelicato DJ, Hossain J, et al. Surveillance imaging in pediatric ependymoma. Pediatr Blood Cancer. 2020;67:e28622.
Bouffet E, Hawkins CE, Ballourah W, et al. Survival benefit for pediatric patients with recurrent ependymoma treated with reirradiation. Int J Radiat Oncol Biol Phys. 2012;83:1541–1548.
Cage TA, Clark AJ, Aranda D, et al. A systematic review of treatment outcomes in pediatric patients with intracranial ependymomas. J Neurosurg Pediatr. 2013;11:673–681.
Armstrong GT, Liu Q, Yasui Y, et al. Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2009;101:946–958.
Neglia JP, Robison LL, Stovall M, et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2006;98:1528–1537.
Upadhyay R, Yadav D, Venkatesulu BP, et al. Risk of secondary malignant neoplasms in children following proton therapy vs. photon therapy for primary CNS tumors: a systematic review and meta-analysis. Front Oncol. 2022;12:893855.